Loading…
Swiss maker of elastomer sealing components, notably rubber closures and syringe seals for pharma packaging.
Swiss maker of elastomer sealing components, notably rubber closures and syringe seals for pharma packaging.
In one line: A niche Swiss West Pharmaceutical Services.
Moat: narrow (regulatory licence, customer qualification, process know-how). Pharma packaging parts require regulatory qualification, locking in suppliers for a drug's life.
Headquarters: Altdorf, Switzerland · Founded: 1915 · Employees: 7,823
Size Daetwyler (DAE.SW) is a Switzerland Industrials company (Miscellaneous Manufacturing) with a market value of $2.72B, the 81st largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 130.80 on 6 Nov 2026.
Performance Over six months the shares fell 21.4%, against -11.3% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 2.0% over the last twelve months (peer median +8.6%); the operating margin is 10.4% (peer median 12.4%).
Valuation It trades at 24.7× forward earnings against a peer median of 19.5× (9th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.8 points above its cost of capital (6.8% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 1.12B | CHF 1.10B | CHF 1.11B | CHF 1.15B | CHF 1.15B |
| Revenue growth | — | -1% | -4% | 0% | — |
| Gross profit | CHF 271M | CHF 258M | CHF 238M | CHF 240M | CHF 255M |
| EBITDA | CHF 193M | CHF 189M | CHF 176M | CHF 179M | CHF 203M |
| Net income | CHF 82.2M | CHF 80.8M | CHF 31.1M | CHF 66.8M | CHF 105M |
| Free cash flow | CHF 119M | CHF 127M | CHF 136M | CHF 143M | CHF 28.6M |
| Capital expenditure | CHF 41.3M | CHF 52.1M | CHF 44.2M | CHF 59.5M | CHF 100M |
| Total debt | n/a | CHF 505M | CHF 574M | CHF 640M | CHF 697M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Daetwyler DAE.SW | $2.72B | -21% | +2% | 10% | 24.7× | 9.3% |
| West Pharmaceutical Services WST | $27.9B | +23% | +13% | 23% | 39.8× | 25.2% |
| AptarGroup ATR | $9.03B | +18% | +9% | 12% | 23.4× | 4.3% |
| Stevanato STVN | $3.70B | -26% | +12% | 18% | 19.3× | 10.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DAE.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.0% | -6.3% | 6th highest of 21 |
| 6-month return | -21.4% | -11.3% | 7th lowest of 21 |
| Distance from 52-week high | -23.8% | -29.5% | 8th highest of 21 |
| Revenue growth (TTM) | +2.0% | +8.6% | 7th lowest of 21 |
| Operating margin | 10.4% | 12.4% | 7th lowest of 21 |
| Forward P/E | 24.7× | 19.5× | 9th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 9.3% | 10.0% | 8th least demanding of 20 |
| Growth delivered (Del g) | +6.0% | +7.7% | 10th lowest of 20 |
| Hurdle (Req g minus delivered) | +3.3 pp | +3.5 pp | 10th least demanding of 20 |
| ROIC minus cost of capital | +4.8 pp | +2.3 pp | 7th highest of 21 |
| EV / EBITDA | 13.9× | 10.5× | 3rd most expensive of 13 |
| Net debt / EBITDA | 2.2× | 0.6× | 2nd most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Daetwyler DAE.SW | Switzerland | $2.72B | -21% | +2% | 10% | 24.7× | 9.3% | +6.0% |
| Hanshow Technology 301275.SZ | China | $2.68B | -5% | +42% | 13% | 27.7× | 10.0% | +13.6% |
| Hill & Smith HILS.L | United Kingdom | $2.88B | +10% | +3% | 16% | 19.5× | 19.4% | +5.6% |
| TOMRA Systems TOM.OL | Norway | $3.17B | +6% | +7% | 11% | 31.8× | 9.5% | +9.2% |
| Zhejiang Weixing New Building Materials 002372.SZ | China | $2.27B | -19% | -12% | 14% | 17.8× | 9.9% | +1.1% |
| Leyard Optoelectronic 300296.SZ | China | $2.20B | -14% | -14% | 4% | 28.8× | 17.1% | +1.2% |
| Zhejiang Weixing Industrial Development 002003.SZ | China | $2.17B | +28% | +14% | 16% | 20.7× | -4.2% | +14.0% |
| Kurita Water Industries 6370.T | Japan | $3.47B | -39% | +1% | 14% | 11.3× | 5.6% | +8.5% |
| Astral ASTRAL.NS | India | $3.57B | -20% | +17% | 12% | 46.8× | 32.5% | +15.6% |
| Brady BRC | United States | $3.69B | 0% | +10% | 16% | 12.0× | 1.0% | +7.7% |
| Supreme Industries SUPREMEIND.NS | India | $4.24B | -14% | +17% | 10% | 33.6× | 25.8% | +12.1% |
| Ansell ANN.AX | Australia | $4.42B | +79% | +2% | 15% | 19.2× | 10.3% | +3.0% |
| FP Corporation 7947.T | Japan | $1.61B | +35% | +4% | 9% | 15.5× | -1.0% | +5.1% |
| Jinfu Technology 003018.SZ | China | $1.51B | -30% | +85% | 26% | 39.3× | 18.0% | +8.2% |
| Vesuvius VSVS.L | United Kingdom | $1.49B | +2% | +2% | 7% | 14.7× | 8.2% | +4.4% |
| Xiamen Voke Mold & Plastic Engineering 301196.SZ | China | $1.48B | -34% | +34% | 12% | 32.6× | 19.6% | +19.4% |
| Shanghai PRET Composites 002324.SZ | China | $1.36B | -44% | +27% | 1% | 45.7× | n/a | n/a |
| Takuma 6013.T | Japan | $1.26B | -1% | +18% | 10% | 13.6× | -5.4% | +2.5% |
| PILLAR 6490.T | Japan | $1.25B | -9% | +10% | 22% | 11.5× | 18.0% | +14.5% |
| China Lesso 2128.HK | Hong Kong | $1.20B | -42% | -5% | 13% | 5.7× | -4.5% | -3.5% |
| Suzhou Victory Precision Manufacture 002426.SZ | China | $1.17B | -41% | +7% | -20% | n/a | 30.8% | -18.0% |